

patients are put on a long-term regimen with these psychostimulants. However some children treated with psychostimulants have reported psychosis as an adverse effect.

Objectives: Understand the capacity of psychostimulant medications to induce psychotic symptoms and determine the frequency of such reactions in adolescents and young adults.

Methods: Non-systematic review of the literature in English, through research in PubMed. Additionally, a clinical case is exposed, which was treated at the psychiatric inpatient unit of the Tamega e Sousa hospital center.

Results: Some patients, including some with no identifiable risk factors, can develop drugrelated signs or symptoms of psychosis or mania, such as hallucinations, at usual doses of frequently used ADHD drugs. Age of onset of psychosis can be significantly earlier in individuals with a history of stimulant use. In our clinical case, a young man of 18 years, previously diagnosed with ADHD, was medicated with atomoxetine two months prior being admitted to our psychiatric unit. There was no reported history of a similar psychiatric condition, and no risk factors were identified. At admission, he had bizarre behavior, with allucinatory activity and delusions of persecution. Atomoxetine was suspended and started oral antipsychotic, with improvement of symptoms and stabilization of the clinical condition.

Conclusions: In adolescents and young adults with ADHD undergoing stimulant therapy, any psychotic symptoms or mood changes need to be carefully assessed at regular intervals by the physicians and the caregivers, in order to observe change in the symptoms.

Disclosure: No significant relationships.

Keywords: First episode psychosis; attention deficit hyperactivity disorder; stimulants

EPV0516

Iatrogenesis in mental health care

M. Sánchez Revuelta*, J. Matsuura, C. Martín Villarroel, L. Carpio Garcia and J. Dominguez Cutanda

Psychiatry, COMPLEJO HOSPITALARIO DE TOLEDO, Toledo, Spain

*Corresponding author.

doi: 10.1192/j.eurpsy.2021.2045

Introduction: The need for preventive mechanisms in psychiatric pathology has been raised, therefore authors talk about primary, secondary and tertiary prevention. However, this emphasis on those preventive aspects has tended to ignore an essential part: quaternary prevention.

Objectives: Reflecting the importance of avoiding ignoring iatrogenic forms of psychopathology by studying a clinical case and reviewing available literature.

Methods: We will present a clinical case of a patient with residual schizophrenia who undergoes an escalation of pharmacological interventions that lead to functional deterioration after initiating behavioral alterations. We will also review available literature about quaternary prevention.

Results: M. is an institutionalized patient who was taking a combination of three neuroleptics, anxiolytics and stabilizers for the treatment of behavior problems such as heteroaggressiveness. When the patient was referred to psychiatry consultations after being hospitalized, he could not move, had lost sphincter control

and had serious communication problems. However, treatment was suspended and only one neuroleptic was maintained. The patient regained sphincter control and kept a residual but communicative delusional speech.

Conclusions: It is important to see how sometimes we can get into therapeutic escalation without correcting the underlying problem by focusing on a symptom, because behavioral alterations will persist regardless of pharmacological treatment changes. Sometimes clinical fluctuations make us confuse basal state and decompensation, ignoring the fact that we lack the way to modify the course. Authors believe that a rational approach to treatment should take into account the balance between potential benefits and side effects applied to an individual patient.

Disclosure: No significant relationships.

Keywords: iatrogenesis; schizofrénia; Psychotropic drugs; side effects

EPV0518

Lorazepam causing drug-induced liver injury : Rare entity

S. Sellami^{1*}, H. Mami¹, M. Moalla², M. Oumaya¹ and R. Bouzid¹

¹Department Of Psychiatry, University hospital of Nabeul, Nabeul, Tunisia and ²Department Of Gastroenterology, University hospital of Nabeul, Nabeul, Tunisia

*Corresponding author.

doi: 10.1192/j.eurpsy.2021.2046

Introduction: Lorazepam is a benzodiazepine derivative that is globally used for the therapy of anxiety and insomnia.

Objectives: The objective of our work was to show that Lorazepam can be a cause of unexpected liver injury even though it is a rare entity.

Methods: We reported the case of a patient who had a Drug-Induced Liver Injury (DILI) under Lorazepam. We performed a literature review based on a PubMed search with the following keywords: "Lorazepam,DILI".

Results: A 20 year-old-Tunisian woman was hospitalized in the psychiatry department of the hospital of Nabeul in Tunisia for a brief psychotic episode. She had a DILI under Olanzapine, Chlorpromazine and Lorazepam, which conducted us to interrupt her treatments except for the Lorazepam(5mg/day). The hepatic tests went back to normal even under Lorazepam. Few days later, the liver enzymes increased again to reach very high levels. Extensive workup was negative for other causes of liver injury, including viral hepatitis A, B, C and E.; capillary electrophoresis of serum proteins was normal; Exhaustive immunological tests were performed searching for auto immune hepatitis(anti-smooth muscle antibodies, anti-LKM1, anti-LC1, anti-SLA/LP) primary biliary cholangitis(anti-mitochondrial antibodies, anti-GP210, anti-sp100) and other antibodies like antinuclear antibodies were negative. Liver biopsy showed polymorphic inflammatory infiltrate including some eosinophilic polynuclear cells and rare vaguely epitheloid macrophages, with necrotico-inflammatory foci in the lobules, all of which were consistent with DILI. Lorazepam was discontinued and within 10 days her liver enzymes decreased and completely normalized.

Conclusions: Lorazepam, with an unknown action mechanism, can be a cause of DILI.

Disclosure: No significant relationships.

Keywords: Lorazepam; DILI; Liver Injury; drug

EPV0519

Dress syndrome following carbamazepine exposure: A very early onset

M. Kraiem^{1*}, N. Charfi², E. Mhiri³, I. Gassara¹, S. Omri², N. Smaoui², R. Feki², L. Zouari², J. Ben Thabet², M. Maalej Bouali² and M. Maalej²

¹Psychiatry C, Hedi Chaker University Hospital, sfax, Tunisia;

²Psychiatry C Department, Hedi chaker University hospital, sfax, Tunisia and ³Hedi Chaker, psychiatry department, sfax, Tunisia

*Corresponding author.

doi: 10.1192/j.eurpsy.2021.2047

Introduction: Drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe cutaneous drug reaction characterised by both systemic and cutaneous clinical manifestation with a mean latency period of 3.9 weeks.

Objectives: To underline the importance of an early diagnosis of DRESS SYNDROME.

Methods: We reported a case of carbamazepine induced DRESS syndrome with atypical chronology of manifestations.

Results: A 43-year-old man with no previous known medical history was admitted in psychiatry. He experienced a relapse of schizoaffective symptoms. In the last three years, the patient was treated by Valproic acid as a mood stabilizer. Because of the unavailability of this molecule, carbamazepine was prescribed in combination with antipsychotics. Three days later, the patient developed a high fever, hypotension, a pruritus, a facial oedema, a skin rash associated to lymphadenopathy. Laboratory findings showed a lymphopenia, eosinophilia and elevated liver chemistries. In order to define the case, RegiSCAR scoring system was used, and our case is categorized as probable with a score of five. Carbamazepine was discontinued upon clinical manifestations and the patient was treated with systemic antihistaminic treatment associated to methylprednisolone with a good outcome. After 3 weeks, clinical and biological improvement were noted.

Conclusions: Despite the absence of a delayed onset, typically between 3 weeks and 3 months, we can diagnose dress syndrome 3 days after carbamazepine intake. This case highlights that psychiatrists should be aware of the risk of early onset dress syndrome associated with carbamazepine and they should monitor for warning symptoms from treatment initiation.

Disclosure: No significant relationships.

Keywords: Dress Syndrome; Carbamazepine; Early onset; eosinophilia

EPV0520

Therapeutic effect of qinghuanling on negative symptoms and cognitive function of schizophrenia

Y. Zhang* and X. Cui

Pharmacy Lab, Xi'an Mental Health Center, Xi'an, China

*Corresponding author.

doi: 10.1192/j.eurpsy.2021.2048

Introduction: Therapeutic effect of Qinghuanling on negative symptoms and cognitive function of schizophrenia

Objectives: To evaluate the therapeutic effect of Qinghuanling on cognitive impairment in schizophrenia, and to provide basis for clinical medication.

Methods: 24 male patients with schizophrenia were randomly divided into study group and control group. The study group was given quetiapine fumarate combined with Qinghuanling, and the control group was given quetiapine fumarate. The positive and negative symptom scale (PANSS) and adverse event response scale (TESS) were evaluated regularly.

Results: The PANSS score of the study group was significantly lower than the control group from 6th week (64.10 ± 7.64 vs 72.31 ± 11.16 ; 51.60 ± 7.40 vs 63.23 ± 7.08 , $P < 0.05$). Among them, the score of negative factor in the study group was significantly lower than that in the control group at the end of 6 and 8 weeks (2.16 ± 0.40 vs 2.75 ± 0.38 ; 1.65 ± 0.42 vs 2.38 ± 0.43 , $P < 0.01$); the score of cognitive factor in the study group was significantly lower than that in the control group at the end of the 8th week (1.87 ± 0.20 vs 2.12 ± 0.27 , $P < 0.05$). Compared with before treatment, PANSS score and symptom cluster factor score of the two groups were significantly decreased from the 2nd weekend to the 8th weekend ($P < 0.05$).

Conclusions: The combined use of Qinghuanling can significantly improve the therapeutic effect of schizophrenia, especially for the symptom cluster score of negative factors and cognitive factors, with high safety.

Disclosure: No significant relationships.

Keywords: Quetiapine; Qinghuanling; Negative factor; Cognitive factor

EPV0521

Efficacy and tolerability of eslicarbazepine acetate as monotherapy in patients of newly diagnosed focal epilepsy

S. Saxena* and S. Singh

Psychiatry, TEERTHANKER MAHAVEER MEDICAL COLLEGE AND RESEARCH CENTRE, MORADABAD, India

*Corresponding author.

doi: 10.1192/j.eurpsy.2021.2049

Introduction: Eslicarbazepine Acetate, a novel anti-epileptic drug has been approved as monotherapy in focal onset seizures, with/without secondary generalization in adults. Eslicarbazepine has many advantages over older anti-epileptic drugs and is useful in patients of new onset focal epilepsy.

Objectives: Aim of our study was to determine the efficacy and safety of Eslicarbazepine Acetate, observe its well-tolerated use and monitor adverse effects in newly diagnosed patients of focal epilepsy.

Methods: Study was done at Department of Psychiatry, Teerthan-ker Mahaveer University, Moradabad. A total of 30 newly diagnosed cases of focal epilepsy between 18-60 years of age were studied for 6 months, using a Semi-structured Interview and Liverpool Adverse Events Profile.

Results: Majority of patients were males (58%), between 21-30 years. Patients with partial/focal seizures (63%) were more common than those of generalized seizures (37%). Majority of the participants had 1-2 episodes of focal seizures weekly (48%), while some had almost daily (32%). Majority were on Eslicarbazepine